{"id":"dlbs3233","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DLBS3233 contains polyphenolic compounds that inhibit hepatic lipogenesis and enhance fatty acid oxidation, thereby reducing intrahepatic triglyceride accumulation. It also exhibits anti-inflammatory and antioxidant properties that may ameliorate liver injury associated with non-alcoholic fatty liver disease (NAFLD).","oneSentence":"DLBS3233 is a bioactive fraction derived from Cinnamomum burmannii that modulates lipid metabolism and reduces hepatic steatosis through multiple pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:52.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-alcoholic fatty liver disease (NAFLD)"}]},"trialDetails":[{"nctId":"NCT07403201","phase":"EARLY_PHASE1","title":"The Effect of Therapy Combination in PCOS With Dlbs 3233","status":"RECRUITING","sponsor":"Inlacinpenelitian","startDate":"2021-12-15","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT01999686","phase":"PHASE3","title":"PCOS Treatment Using DLBS3233, Metformin, and Combination of Both","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2014-10","conditions":"Polycystic Ovary Syndrome (PCOS), Insulin Resistance","enrollment":186},{"nctId":"NCT01733459","phase":"PHASE3","title":"Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2013-03","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":124},{"nctId":"NCT01645332","phase":"PHASE3","title":"Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2012-07","conditions":"Type-2-diabetes Mellitus, New Onset","enrollment":104},{"nctId":"NCT01472614","phase":"PHASE3","title":"Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2011-09","conditions":"Type-2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT01531933","phase":"PHASE3","title":"Efficacy and Safety of DLBS3233 in Prediabetic Patients","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2011-11","conditions":"Prediabetic","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inlacin"],"phase":"phase_3","status":"active","brandName":"DLBS3233","genericName":"DLBS3233","companyName":"Dexa Medica Group","companyId":"dexa-medica-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DLBS3233 is a bioactive fraction derived from Cinnamomum burmannii that modulates lipid metabolism and reduces hepatic steatosis through multiple pathways. Used for Non-alcoholic fatty liver disease (NAFLD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}